TCR-Therapy Pipeline

DelveInsight’s, “TCR Therapy Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in TCR Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

TCR Therapy Understanding

TCR Therapy Overview

The T-cell receptor (TCR) is a surface molecule on T lymphocytes that recognizes antigen fragments presented as peptides bound to major histocompatibility complex (MHC) molecules. Although TCR–peptide interactions are relatively low in affinity, they are highly versatile, allowing multiple TCRs to recognize the same peptide and vice versa. The human and mouse TCRs were independently discovered in 1984 by Tak Wah Mak and Mark M. Davis, a breakthrough that transformed immunology and advanced fields such as CAR-T therapy, cancer immunotherapy, and checkpoint inhibition. Structurally, the TCR is a heterodimer composed predominantly of alpha (α) and beta (β) chains in about 95% of human T cells, while the remaining 5% contain gamma (γ) and delta (δ) chains; these proportions vary across development, disease states, and species. Upon binding to peptide–MHC complexes, the TCR initiates signal transduction pathways that activate T cells through coordinated biochemical and transcriptional events.

The T-cell receptor (TCR) is a membrane-bound, disulfide-linked heterodimeric protein composed primarily of highly variable alpha (α) and beta (β) chains associated with invariant CD3 molecules, while a smaller subset of T cells expresses gamma (γ) and delta (δ) chains. Each chain contains variable (V) and constant (C) extracellular domains belonging to the immunoglobulin superfamily, followed by a transmembrane region and a short cytoplasmic tail. Antigen recognition occurs through hypervariable complementarity-determining regions (CDRs), particularly CDR3, which plays the central role in recognizing peptide antigens presented by MHC molecules, whereas other CDRs contribute to peptide and MHC interactions. Structurally and functionally, the TCR resembles a membrane-anchored half-antibody but relies on associated CD3 and zeta chains for signal transduction due to its short intracellular tail. TCR diversity arises through somatic V(D)J recombination mediated by RAG1 and RAG2 during T-cell development, generating highly variable CDR3 regions through junctional diversity while other CDRs remain germline encoded.
Although T-cell receptor (TCR) gene rearrangement was once thought to be entirely random, studies now show that αβ T-cell repertoire diversity is tightly regulated even before thymic selection. Genetic and epigenetic mechanisms, including chromatin remodeling, DNA methylation, histone modification, and locus accessibility, influence V(D)J recombination and shape repertoire composition. Evidence from mouse studies further demonstrates recombinatorial bias in V and J segment usage, resulting in shared TCR sequences across individuals independent of thymic selection or MHC haplotype, highlighting that TCR diversity is a structured and controlled process rather than a purely stochastic one.

Following successful rearrangement, T-cell receptors (TCRs) undergo thymic selection against self-peptide–MHC complexes, allowing only a small fraction of thymocytes to mature and enter the periphery. The diversity of the post-selection repertoire is shaped by MHC polymorphism, peptide presentation, and antigen-processing mechanisms such as ERAP1-mediated peptide trimming, all of which influence the peptides available for T-cell selection. Studies in mice and humans demonstrate that both genetic and environmental factors contribute to TCR repertoire formation, with alterations in repertoire diversity linked to autoimmune diseases and regulatory T-cell dysfunction. Twin and disease studies further reveal that although genetic background strongly influences early repertoire similarity, individual antigen exposure and immune history progressively shape distinct, highly personalized TCR repertoires over time.

The T-cell receptor (TCR) complex is an octameric structure composed of antigen-recognizing αβ or γδ TCR chains associated with CD3 and ζ signaling modules that mediate intracellular signal transduction. TCRs specifically recognize peptide–MHC (pMHC) complexes on antigen-presenting or target cells with high specificity despite relatively low binding affinity, and signaling sensitivity is enhanced through co-receptors CD4 and CD8, which interact with MHC class II and class I molecules, respectively. Upon antigen recognition, kinases such as Lck, Fyn, and ZAP-70 activate downstream signaling cascades involving LAT, PLC-γ1, NFAT, MAPK, and NF-κB pathways, leading to T-cell activation, proliferation, and cytokine production. Advances in understanding TCR signaling and antigen recognition have enabled the development of TCR-engineered T-cell therapies, in which patient-derived T cells are genetically modified to express tumor-specific TCRs capable of targeting cancer antigens such as NY-ESO-1, MAGE, MART-1, and gp100. These engineered T cells demonstrate significant therapeutic potential in adoptive cancer immunotherapy, while modern single-cell sequencing and cloning approaches facilitate the identification and characterization of clinically relevant tumor-specific TCRs.

"TCR Therapy Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TCR Therapy pipeline landscape is provided which includes the disease overview and TCR Therapy treatment guidelines. The assessment part of the report embraces, in depth TCR Therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TCR Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

TCR Therapy Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence TCR Therapy R&D. The therapies under development are focused on novel approaches to treat/improve TCR Therapy.

TCR Therapy Emerging Drugs Analysis

This segment of the TCR Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TCR Therapy Emerging Drugs

IMC F106C: Immunocore

IMC-F106C, also known as brenetafusp, is an innovative immune-mobilizing monoclonal T cell receptor (ImmTAC) designed to target cancers that express the tumor-associated antigen PRAME (Preferentially Expressed Antigen in Melanoma). This bispecific protein functions by redirecting T cells to recognize and attack cancer cells presenting the PRAME peptide through the HLA-A*02:01 protein. Initial results from the trial indicate promising clinical activity, particularly among patients with PRAME-positive tumors. In a cohort of heavily pre-treated metastatic cutaneous melanoma patients, the clinical benefit rate was reported at 61%, with a median progression-free survival (PFS) of 4.5 months for PRAME-positive patients compared to 2.1 months for those who were PRAME-negative. Currently the drug is in Phase III stage of clinical trial evaluation for the treatment of patients with 1L advanced, cutaneous melanoma.

RPTR-1-201: Repertoire Immune Medicines

RPTR-1-201 is a TCR bispecific molecule that combines an engineered TCR, designed to bind a tumor-selective epitope with high affinity and specificity, with an anti-CD3 component that redirects T cells to eliminate tumor cells. Developed using Repertoire’s DECODE™ platform, it leverages immune synapse mapping to identify TCR-epitope pairs and transform these insights into targeted T cell-based immunotherapies. RPTR-1-201 is currently being evaluated in a Phase I/II clinical trial as monotherapy and in combination with an anti-PD-1 therapy in participants with advanced solid tumors.

TSC-100: TScan Therapeutics

TSC-100 is an investigational TCR-engineered T cell therapy developed by TScan Therapeutics for the treatment of hematologic malignancies such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndromes (MDS). The therapy targets the minor histocompatibility antigen HA-1 to eliminate residual malignant cells and reduce relapse risk following allogeneic hematopoietic cell transplantation (HCT). Developed using TScan’s proprietary ReceptorScan platform, TSC-100 is designed to selectively destroy patient-derived cancer cells while sparing healthy donor cells, with early Phase I clinical data demonstrating encouraging safety, durable donor chimerism, and sustained minimal residual disease negativity, supporting its potential as a targeted post-transplant immunotherapy. Currently, the drug is in Phase I stage of its development for the treatment AML and Myelodysplastic Syndromes.

ADP-600: Adaptimmune

ADP-600 is a preclinical engineered TCR T-cell therapy developed by Adaptimmune targeting PRAME, a cancer-testis antigen highly expressed across multiple solid tumors, including synovial sarcoma, breast, non-small cell lung cancer (NSCLC), gastroesophageal, melanoma, endometrial, ovarian, and head and neck cancers. Developed as part of Adaptimmune’s next-generation TCR-T cell therapy pipeline, ADP-600 is designed to recognize and eliminate PRAME-positive tumor cells with high sensitivity and specificity. Preclinical studies demonstrated potent anti-tumor activity, robust T-cell proliferation, and approximately 10-fold greater peptide sensitivity compared to competing PRAME-targeted candidates, supporting its potential as a best-in-class therapy for PRAME-expressing malignancies. The program is currently in Preclinical stage of development for indications that express PRAME including synovial sarcoma, breast, NSCLC, gastroesophageal, melanoma, endometrial, ovarian and head & neck cancers, and clinical indications like TBD.

Further product details are provided in the report……..

TCR Therapy Drug Therapeutic Assessment

This segment of the report provides insights about the different TCR Therapy drugs segregated based on following parameters that define the scope of the report, such as:

Major TCR Therapy Players in TCR Therapy

There are approx. 50+ key companies which are developing the therapies for TCR Therapy. The companies which have their TCR Therapy drug candidates in the most advanced stage, i.e. Phase III include, Immunocore.

TCR Therapy Clinical Trial Phases

DelveInsight’s report covers around 55+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

TCR Therapy Drug Route of Administration

TCR Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

TCR Therapy Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

TCR Therapy Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TCR Therapy Clinical Trial Activities 

The TCR Therapy Pipeline report provides insights into different TCR Therapy Clinical Trial within Phase III, II, I, preclinical and discovery stage. It also analyses TCR Therapy therapeutic drugs key players involved in developing key drugs.

TCR Therapy Pipeline Development Activities

The TCR Therapy Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TCR Therapy drugs.

TCR Therapy Pipeline Report Insights

• TCR Therapy Pipeline Analysis
• TCR Therapy Therapeutic Assessment
• TCR Therapy Unmet Needs
• Impact of TCR Therapy Drugs

TCR Therapy Pipeline Report Assessment

• TCR Therapy Pipeline Product Profiles
• TCR Therapy Therapeutic Assessment
• TCR Therapy Pipeline Assessment
• TCR Therapy Inactive drugs assessment
• TCR Therapy Market Unmet Needs

Key Questions Answered In the TCR Therapy Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing TCR Therapy drugs?
• How many TCR Therapy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TCR Therapy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TCR Therapy therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for TCR Therapy and their status?
• What are the key designations that have been granted to the emerging drugs?

TCR Therapy Key Players

• Immunocore
• Repertoire Immune Medicines
• SCG Cell Therapy
• Immatics Biotechnologies GmbH
• TScan Therapeutics
• Corregene Biotechnology Co.
• Treadwell Therapeutics
• Adaptimmune
• Takara Bio
• Triumvira
• Immatics
• JW Therapeutics
• AstraZeneca
• BlueSphere Bio
• Zelluna
• Anocca

TCR Therapy Key Products

• IMC F106C
• RPTR-1-201
• SCG 101
• SCG 162
• IMA402
• TSC-100
• CRTE7A2-01
• Research Program: TCR-BASED CELL THERAPY
• ADP-600
• TBI 1301
• TAC01 CLDN18.2
• IMA402
• ECT204
• NT-175
• TCX-101
• TCX-102
• ZI-MA4-1
• ZI-KL1-1
• A*11:01 : G12V